Search Results
Your search for Staff matches 6667 pages
Showing 5001 - 5050AMA Board of Trustees Pledges Action Against Racism and Police Brutality
At a virtual Special Meeting of the American Medical Association (AMA) House of Delegates, the AMA Board of Trustees pledged action to confront systemic racism and police brutality. The AMA released the following statement that was approved at its meeting on June 5, 2020: The AMA recognizes that...
New Information From NCCN on Overcoming Challenges for People With Head and Neck Cancer
The National Comprehensive Cancer Network® (NCCN®) has now published a third book to complete the NCCN Guidelines for Patients®: Head and Neck Cancers series. Each book contains detailed, expert guidance on what to expect and management options for various cancers that impact the mouth and throat....
Advanced Practitioner Society Issues Statement Against Systemic Racism, Discrimination
In further statements from professional oncology organizations about inequities and disparities among racial and ethnic minorities and underserved populations, as well as racism and discrimination, the Advanced Practitioner Society for Hematology and Oncology (APSHO) issued the following ...
NCI Renews Comprehensive Cancer Center Designation for Norris Cotton Cancer Center
The National Cancer Institute (NCI) has renewed its Cancer Center Support Grant to Dartmouth and Dartmouth-Hitchcock Norris Cotton Cancer Center (NCCC). The 5-year, $15.5 million grant will provide continued support for NCCC’s clinical care and research missions. NCI recognized the cancer center...
Special Report Provides Guidance to Oncology Practices on Resuming Care During the COVID-19 Pandemic
As pandemic-related restrictions gradually begin to ease, oncology practices are trying to understand how to safely restore patient access to critical cancer care services. In response, ASCO released the ASCO Special Report: A Guide to Cancer Care Delivery During the COVID-19 Pandemic, which...
AACR Stands Against Racial Discrimination and Inequality
On June 4, 2020, the American Association for Cancer Research (AACR) released this statement: [AACR] is outraged and saddened about the pervasive racism and social injustices toward African Americans in our country and all people of color around the world. As a scientific organization focused on...
Small Study Finds Olanzapine Reduces Nausea and Vomiting Caused by Advanced Cancer
The antipsychotic agent olanzapine may be helpful in reducing nausea and vomiting caused by advanced cancer, according to results of a study by Loprinzi et al published recently in JAMA Oncology. “There was a dramatic reduction [in nausea and vomiting] within 24 hours in the people who received...
Penn Medicine Announces Appointment of Daniel Yoshor, MD, as Chair, Department of Neurosurgery
Neurosurgeon and neuroscientist Daniel Yoshor, MD, has been named Chair of the Department of Neurosurgery in the Perelman School of Medicine at the University of Pennsylvania and Vice President of Clinical Integration and Innovation for the University of Pennsylvania Health System in Philadelphia. ...
American Urological Association Recognizes Roswell Park Surgeon Eric Kauffman, MD
Eric Kauffman, MD, was recently recognized by the American Urological Association for his novel approach to prostate cancer surgery, receiving a Best Video award for 2020. Dr. -Kauffman is a surgeon in the Department of Urology at Roswell Park Comprehensive Cancer Center, Buffalo. His video...
Seattle Cancer Care Alliance Opens New Clinic Dedicated to Gastrointestinal Cancer Care
Seattle Cancer Care Alliance (SCCA) announced the opening of a Gastrointestinal (GI) Care Neighborhood, a new cancer clinic aimed at improving the experience for patients with GI cancers, which features dedicated GI-related cancer care services on one floor of SCCA’s South Lake Union campus. “We...
Study Confirms Effective, Less-Toxic Alternative to Standard Treatment of Adults With Burkitt Lymphoma
In a recent study reported in the Journal of Clinical Oncology,1 an alternative treatment regimen that is less toxic than standard dose-intensive chemotherapy was found to be highly effective for adults with Burkitt lymphoma across all age groups and independent of HIV status. In addition to being...
Woman With an Ovarian Tumor
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era: 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Study Identifies Potential Approach to Treat Severe Respiratory Distress in Patients With COVID-19
Early data from a clinical study published in Science Immunology1 suggest that blocking the Bruton’s tyrosine kinase (BTK) protein provided clinical benefit to a small group of patients with severe COVID-19 infection.1 Roschewski et al observed that the off-label use of the BTK inhibitor...
Survey Shows Young-Onset Colorectal Cancer May Be Overlooked in Exam Rooms
The Colorectal Cancer Alliance recently released findings from its latest survey of patients with young-onset colorectal cancer and survivors. The Never Too Young Survey shares the self-reported medical, psychosocial, and quality-of-life experiences of this often-overlooked population to better...
ASCO20 Virtual Scientific Program: Next-Generation Oncology Highlights
The ASCO20 Virtual Scientific Program was different in many ways, not only because of the virtual modality forced by the COVID-19 pandemic, but also because of the resilience of the scientific society and my colleagues around the world. I’m in the plenary session of the ASCO 2025 Annual Meeting....
American Association for Cancer Research Announces Distinguished Public Service Award Recipients
The American Association for Cancer Research (AACR) recently announced the presentation of Distinguished Public Service Awards to four individuals whose work has exemplified the AACR’s mission to prevent and cure all cancers through research, education, communication, collaboration, science policy, ...
MSK–Hackensack Meridian Health Partnership Collaborate on Immunology Research Projects
Memorial Sloan Kettering Cancer Center (MSK) and Hackensack Meridian Health recently announced they have formed an Immunology Research Collaboration. Through this joint initiative, researchers can apply for funding to support innovative investigations exploring the power of the immune system and...
Jackson Laboratory Cancer Center Receives Continued Recognition, Funding by NCI
The Jackson Laboratory (JAX), a basic science research center with locations throughout the state of Maine, recently announced the National Cancer Center has renewed its Cancer Center Support Grant for the 34th year. The Jackson Laboratory is one of seven basic research centers with this...
Fox Chase–Temple University Hospital Announces Bone Marrow Transplant Program
The Fox Chase–Temple University Hospital Bone Marrow Transplant (BMT) Program recently announced it will introduce a Department of Bone Marrow Transplant and Cellular Therapies on July 1, 2020. Henry Chi Hang Fung, MD, FACP, FRCPE, Current Director of the Bone Marrow Transplant Program and Vice...
Cancer Researcher Grzegorz Ira, PhD, Honored With Baylor’s DeBakey Award
Select Baylor College of Medicine faculty are honored annually through the Michael E. DeBakey, MD, Award for Excellence in Research for outstanding published scientific contributions to clinical and basic science research over a 3-year period. Included among the honorees for this year’s DeBakey...
AACR Inaugurates New Leadership
The American Association for Cancer Research (AACR) welcomes Antoni Ribas, MD, PhD, FAACR, as President of the organization for 2020–2021. He was inaugurated during the AACR Annual Business Meeting, held virtually on April 29, 2020. Dr. Ribas is Professor of Medicine at the David Geffen School of...
Ganesh Rao, MD, Named Chair of Neurosurgery at Baylor College of Medicine
Baylor College of Medicine recently announced that Ganesh Rao, MD, has been named the new Chair of the Department of Neurosurgery. In this role, he also will hold the Marc J. Shapiro Endowed Chair at Baylor and will serve as the Neurosurgery Service Line Chief across the Catholic Health...
Blood Test Improves Screening for Hepatocellular Carcinoma
Researchers at the National Institutes of Health have developed a new test that may help identify individuals who may be likely to develop hepatocellular carcinoma. A study of the new approach was led by researchers at the National Cancer Institute (NCI). The findings were published in the journal...
Global Study Indicates Oncology Pharmacists Face Restricted Access to Essential PPE
Oncology pharmacy practitioners around the world are fighting to provide patients who have cancer with high-quality care despite increasingly limited and sometimes restricted personal protective equipment (PPE) as well as impaired access to essential anticancer medication, according to study...
ASCO Survey on Early Impact of COVID-19 on Performance of Oncology Clinical Trials
In an article published in JCO Oncology Practice, David Waterhouse, MD, MPH, of Oncology Hematology Care, Cincinnati, Ohio, and colleagues presented the results of a recent ASCO survey of clinical programs on the early impact of the COVID-19 pandemic on the performance of oncology clinical...
Northwell Health Cancer Institute of New York Appoints Oncology Experts to Lead New Programs
The Northwell Health Cancer Institute of Northwell Health in New Hyde Park, New York, has recruited four experts to strengthen its cancer care management, survivorship programs, oncology nursing, cancer research, and oncology surgery at locations throughout Long Island and Westchester county:...
ASCO20 Virtual Scientific Program Convened Record Number of Oncology Professionals From Across the Globe
ASCO announced record-breaking attendance at its 3-day ASCO20 Virtual Scientific Program, held online from May 29 through May 31. More than 42,700 attendees from 138 countries have participated thus far, learning virtually about new clinical cancer advances in every area of cancer research....
FDA Approves Pembrolizumab for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma
On June 24, the U.S. Food and Drug Administration (FDA) approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable with surgery or radiation. KEYNOTE-629 Efficacy was investigated in KEYNOTE-629, a multicenter, multicohort,...
International Consortium Aims to Enhance Decision-Making in Hodgkin Lymphoma
Harmonization of big data in examining acute and long-term outcomes with contemporary treatment for pediatric and adult patients with Hodgkin lymphoma is yielding a new approach to inform future clinical trial design and enhance clinical decision-making, according to a statement by Rutgers Cancer...
Underrepresentation of Black Patients in Cancer Clinical Trials: Public vs Pharmaceutical Sponsorship
Black patients are better represented in taxpayer-funded cancer clinical trials compared to trials run by pharmaceutical companies, although they remain underrepresented in clinical trials, regardless of sponsor. These results were published by Joseph M. Unger, PhD, and colleagues in JNCI Cancer...
FDA Announces Project Patient Voice to Communicate Patient-Reported Outcomes From Cancer Clinical Trials
The U.S. Food and Drug Administration (FDA) has launched Project Patient Voice, an initiative of the FDA’s Oncology Center of Excellence (OCE). Through a new website, Project Patient Voice creates a consistent source of publicly available information describing patient-reported symptoms from cancer ...
Paul G. Richardson, MD, on Multiple Myeloma: First-in-Human Study of the Novel Agent CC-92480
Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses early results on a cereblon E3 ligase modulator agent combined with dexamethasone in patients with relapsed or refractory multiple myeloma, with an overall response rate of 48%. The study is ongoing to further optimize dose and...
Patricia Pautier, MD, on Leiomyosarcoma: Doxorubicin and Trabectedin for First-Line Treatment
Patricia Pautier, MD, of Institut Gustave Roussy, discusses final results of the phase II LMS-02 study, which showed the combination of doxorubicin and trabectedin to be an effective first-line therapy for patients with leiomyosarcoma, with an acceptable safety profile (Abstract 11506).
Nikhil C. Munshi, MD, on Multiple Myeloma: Idecabtagene Vicleucel in Patients With Relapsed or Refractory Disease
Nikhil C. Munshi, MD, of Dana-Farber Cancer Institute, discusses initial results from the KarMMa tria, showing that idecabtagene vicleucel, a B-cell maturation antigen-targeted CAR T-cell therapy, demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory...
Study Links Financial Hardship to More Emergency Room Visits, Less Preventive Care Among Cancer Survivors
A new study has found higher medical and nonmedical financial hardships are independently associated with more emergency department visits, lower receipt of some preventive services, and worse self-rated health in cancer survivors. The authors of the study warn that as health-care costs grow, unmet ...
Lipophilic Statins May Reduce Mortality in Patients With Ovarian Cancer
Lipophilic statins—a type of medication commonly prescribed to lower blood cholesterol—were associated with reduced mortality in patients with ovarian cancer, according to a study presented by Kala Visvanathan, MD, MHS, and colleagues at the American Association for Cancer Research (AACR) Virtual...
ASTRO Issues Clinical Guideline on Radiation Therapy for Cervical Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides recommendations for radiation therapy to treat patients with nonmetastatic cervical cancer. The guideline—ASTRO's first for cervical cancer—outlines indications and best practices for external-beam radiation...
FDA Approves Selinexor for Relapsed or Refractory DLBCL
On June 22, the U.S. Food and Drug Administration (FDA) approved oral selinexor (Xpovio), a first-in-class, selective inhibitor of nuclear export compound, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified after at least...
Parameswaran Hari, MD, on Multiple Myeloma: Post-Autologous Hematopoietic Cell Transplantation Strategies in Upfront Treatment
Parameswaran Hari, MD, of the Medical College of Wisconsin, discusses phase III data from a 6-year follow-up of the STaMINA trial, which compared progression-free survival among 758 patients with high-risk multiple myeloma who received a second autologous transplant and lenalidomide maintenance;...
Peter Reichardt, MD, PhD, on GIST: Adjuvant Imatinib for High-Risk Disease
Peter Reichardt, MD, PhD, of Helios Klinikum Berlin-Buch, discusses the 10-year survival analysis of 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumor. The study found that about 50% of deaths can be avoided with longer imatinib treatment (Abstract...
Egbert F. Smit, MD, PhD, on NSCLC: Treatment With Fam-trastuzumab Deruxtecan
Egbert F. Smit, MD, PhD, of the Netherlands Cancer Institute, discusses interim results from the DESTINY-Lung01 trial of fam-trastuzumab deruxtecan in patients with HER2-mutated metastatic non–small cell lung cancer. The data show clinical activity with high overall response rates and durable...
Lakshmi Nayak, MD, on Primary CNS Lymphoma: The Search for Optimal First-Line Treatment
Lakshmi Nayak, MD, of Dana-Farber Cancer Institute, reviews two key abstracts on newly diagnosed primary central nervous system lymphoma and treatment with whole-brain radiotherapy, methotrexate, temozolomide, rituximab, procarbazine, vincristine, and cytarabine (Abstracts 2500 and 2501).
FDA Pipeline: Fast Track Designations in Colorectal and Pancreatic Cancers, Lymphoplasmacytic Lymphoma/Waldenström’s Macroglobulinemia
Over the past month, the U.S. Food and Drug Administration has granted Fast Track designation to agents designed to treat colorectal and pancreatic cancers, in addition to lymphoplasmacytic lymphoma/Waldenström’s macroglobulinemia; accepted a new drug application for a treatment for relapsed or...
SIR 2020 Virtual: Transarterial Chemoperfusion for Patients With Mesothelioma
A novel treatment for patients with advanced mesothelioma is safe and effective and may improve the quality of life for patients who have few treatment options, according to a research abstract presented during a virtual session of the Society of Interventional Radiology (SIR) 2020 Annual...
SIR 2020 Virtual: Holographic Visualization for Ablation of Liver Tumors
Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of...
Suresh S. Ramalingam, MD, on NSCLC: Nivolumab Plus Ipilimumab vs Chemotherapy
Suresh S. Ramalingam, MD, of Emory University, discusses a 3-year update from the CheckMate 227, Part 1, trial, which showed that nivolumab plus ipilimumab continued to provide durable and long-term overall survival benefit vs platinum-doublet chemotherapy as first-line treatment for patients with...
Nirav Niranjan Shah, MD, on DLBCL: Autologous Transplant vs CAR T-Cell Therapy
Nirav Niranjan Shah, MD, of the Medical College of Wisconsin, explores whether autologous transplantation, in patients with relapsed diffuse large B-cell lymphoma who achieve only a PET/CT-positive partial remission, is appropriate in the era of CAR T-cell therapy (Abstract 8000).
FDA Grants Accelerated Approval to Tazemetostat for Some Patients With Follicular Lymphoma
On June 18, the U.S. Food and Drug Administration (FDA) granted accelerated approval to tazemetostat (Tazverik), an EZH2 inhibitor, for adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have...
Percutaneous Cryoablation vs Partial or Radical Nephrectomy for Early-Stage Kidney Cancer
A minimally invasive procedure that destroys cancer cells by freezing them may be an option other than surgery for treating early-stage kidney cancer. The two methods showed similar 10-year survival rates, with cryoablation showing a lower rate of complications, according to a study published by...
Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease
Rachel E. Sanborn, MD, of the Providence Cancer Institute, discusses three key abstracts on EGFR-mutated non–small cell lung cancer: a final overall survival analysis of bevacizumab plus erlotinib; concurrent osimertinib plus gefitinib for first-line treatment; and first-line treatment with a...
